Epigenetic mechanisms underlying tumorigenesis have recently received much attention as potential therapeutic targets of human cancer. We designed a pilot study to target DNA methylation and histone deacetylation through the sequential administration of 5-azacytidine followed by sodium phenylbutyrate (PB) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Ten evaluable patients (eight AML, two MDS) were treated with seven consecutive daily subcutaneous injections of 5-azacytidine at 75 mg/m 2 followed by 5 days of sodium PB given intravenously at a dose of 200 mg/kg. Five patients (50%) were able to achieve a beneficial clinical response (partial remission or stable disease). One patient with MDS proceeded to allogeneic stem cell transplantation and is alive without evidence of disease 39 months later. The combination regimen was well tolerated with common toxicities of injection site skin reaction (90% of the patients) from 5-azacytidine, and somnolence/fatigue from the sodium PB infusion (80% of the patients). Correlative laboratory studies demonstrated the consistent reacetylation of histone H4, although no relationship with the clinical response could be demonstrated. Results from this pilot study demonstrate that a combination approach targeting different mechanisms of transcriptional modulation is clinically feasible with acceptable toxicity and measurable biologic and clinical outcomes.
Introduction
Epigenetic mechanisms that can dysregulate gene expression have become increasingly attractive as potential targets in the therapy of human cancer. 1, 2 Fusion products of leukemiaassociated translocations have been shown to dysregulate gene expression at least, in part, by binding histone deacetylases (HDACs) and DNA methyltransferases (Dnmts). These proteins (acute myeloid leukemia (AML)1-ETO, PML-RARa) can effect epigenetic silencing of key genes associated with fundamental cellular processes that contribute to the transformed phenotype. [2] [3] [4] [5] Histone acetylation has been shown to be a critical factor in promoting gene transcription, as histone (hyper)acetylation induces a conformational relaxation in tightly coiled DNA facilitating the binding of transcriptional activators. In contrast, histone deacetylation has been linked to gene repression. These processes are readily reversible and the balance of HDACs and histone acetyltransferase activity determines the state of histone tail acetylation. An aberrant methylation status of DNA regulatory promoter sequences (CpG islands), including those found in putative tumor suppressor genes, has been implicated in the process of carcinogenesis, as well. DNA methylation represents a more stable epigenetic mark.
The past two decades have seen fundamental regulatory processes gain clinical relevance as agents have been introduced, which target the mechanisms discussed above. The efficacy of all-trans retinoic acid (ATRA) in treating acute promyelocytic leukemia (APL) is due to its ability to bind to PML-RARa, and displace the mSin-3/N-CoR/HDAC deacetylation complex that causes transcriptional repression. [6] [7] [8] Retinoid resistance can result from point mutations in the RARa portion of the PML-RARa fusion product, which affect the ability to bind ATRA. Furthermore, ATRA cannot displace the corepressor/ HDAC complex from the variant PLZF-RARa fusion protein.
Directly targeting the HDAC complex could overcome some forms of clinical resistance to RA and this has been shown in vitro using ATRA-resistant NB4 cells, where resistance can be reversed by combining RA with the HDAC inhibitor trichostatin A. [6] [7] [8] [9] While a number of HDAC inhibitors have been tested ex vivo, the use of such agents in humans has been somewhat problematic because of toxicities such as QT interval prolongation. Sodium phenylbutyrate (PB) is a drug that was initially used in humans for the treatment of thalassemia and certain hyperammonemic states. 10, 11 In vitro, PB and its principal metabolite, phenylacetate (PA), can induce cellular differentiation at plasma concentrations attained in children given intravenous (i.v.) PB for hyperammonemia. [12] [13] [14] Other in vitro studies have shown that PB acts synergistically with retinoic acid (RA) to induce cytodifferentiation 15 (Weng LJ et al. Blood 1996 ; 90: 326a; abstract).
The interest in cytodifferentiation as a goal of cancer therapy prompted a number of preliminary studies using either PB or PA. When used as a single agent, neither drug was clinically effective. [16] [17] [18] [19] [20] However, their ability to induce reversible histone deacetylation suggested their possible use in combination therapy. An index patient with highly resistant APL treated with the combination of PB and ATRA achieved a complete clinical, cytogenetic and molecular remission. 21 However, subsequent patients failed to respond to this regimen, underscoring the fundamental complexity of clinical drug resistance and the need to develop strategies that target transcriptional repression through multiple different mechanisms. 22 Hypermethylation of CpG islands in the promoter region of tumor suppressor genes has been proposed as a mechanism contributing to carcinogenesis in a wide variety of human tumors. These data prompted clinical investigation into a series of compounds with hypomethylating action. [2] [3] [4] [5] Recently, a number of studies have reported the results of two such agents, 5-azacytidine and 5-aza-2 0 -deoxycytidine (decitabine), in the treatment of patients with myelodysplastic syndrome (MDS) and myeloid leukemias. 23, 24 In 2004, the US Food and Drug Administration approved 5-azacytidine for therapeutic use in MDS. Preliminary results of a large phase III study of decitabine versus supportive care in advanced MDS reported a 25% response rate in the decitabine group with an acceptable toxicity profile and improved outcomes in the high-risk MDS patients (Saba H et al. Blood 2004; 104: 23a; abstract). Issa et al. recently reported a phase I study, using a prolonged (5-day) administration schedule of low-dose decitabine in patients with AML and MDS, that achieved complete remission (CR) rates of 14 and 29%, respectively. Despite significant demethylation of the p15 or p16 genes in patients who were initially shown to have high levels of methylation, no correlation was found between the effect on methylation and clinical response. 24 Combination DNA hypomethylating (decitabine) and histone deacetylatase (HDAC) inhibition therapy has been shown to synergistically induce re-expression of hypermethylated silenced tumor suppressor genes in human cancer cells and to prevent the formation of lung tumors in an experimental murine model. 25, 26 To test the concept that combination therapy targeted against distinct, but related mechanisms of gene repression could be a clinically feasible strategy, we designed a pilot study, investigating sequential therapy with the hypomethylating agent 5-azacytidine followed by the HDAC inhibitor, sodium PB in patients with MDS and relapsed/ refractory acute myeloid leukemia. The following report details the clinical and laboratory results of this trial.
Materials and methods
The primary clinical objective of this study was to investigate the safety and biological activity of the combination of 5-azacytidine and sodium PB. Correlative laboratory studies were performed to evaluate their effects on histone acetylation.
Eligibility
Confirmation of a diagnosis of either acute myelogenous leukemia or MDS, at Memorial Sloan-Kettering Cancer Center, was required for participation in this study. Patients could have either: (1) failed conventional therapy, (2) AML that relapsed after achieving a CR or (3) been ineligible for standard induction therapy or had no other potentially curative treatment available. The Karnofsky performance status was required to be X60%. Serum creatinine and total bilirubin were both required to be p2.5 mg/dl. Women of child-bearing age were required to have a negative pregnancy test. Patients were required to provide signed informed consent on an Institutional Review Boardapproved protocol.
Treatment plan
Following registration and baseline clinical evaluation, patients received 7 consecutive days of 5-azacytidine (75 mg/m 2 ) administered by subcutaneous injection. Patients then began 5 consecutive days of therapy with sodium PB, which was administered at a dose of 200 mg/kg over 1-2 h i.v. Blood and bone marrow samples were obtained and patients were tested for the extent of basal histone hyperacetylation before beginning the 5-azacytidine. On day 8, bone marrow and/or peripheral blood samples were again obtained for repeat histone acetylation assays. At the end of the fifth day of the PB infusion, samples for the acetylation assays were again obtained. The doses of both drugs on this study were fixed. Patients who sustained a beneficial clinical response (CR or partial remission (PR) or stable disease (SD)) received a second cycle of treatment that began approximately 10 days after the last dose of sodium PB. Subsequent cycles of therapy were repeated after 21-28 days had elapsed from the before treatment cycle, depending upon satisfactory tolerance to the drugs and no progression of the underlying disease. Testing for the histone acetylation from the patient blood and/or bone marrow samples was only performed during the first cycle of therapy.
Evaluation during therapy
All patients had baseline evaluation including a medical history and physical examination as well as complete blood count (including differential) and a comprehensive biochemical profile. A bone marrow aspiration was obtained and sent for routine diagnostic studies including immunophenotyping and cytogenetics. CBCs and comprehensive biochemical profiles were also required at the end of the 5-azacytidine therapy, upon completion of the sodium PB infusion, and once between days 15 and 28. Patient samples from blood and/or bone marrow were also assessed for histone acetylation (described below). Such testing was only performed during the first cycle of therapy.
Response criteria
For the purpose of this study, responses were divided into three major criteria: CR, PR and SD. CR was defined in accordance with standard consensus criteria for blood and bone marrow. 27 PR was defined as a decrease in the blast count by 50% or more compared to the pretreatment count. Cellularity and morphology were not relevant in categorizing this response. SD was defined either as failure to achieve at least a PR, or without evidence of progression for at least 1 month following before therapy. Relapse after CR or PR was defined by one or more of the following: return to pretreatment blast count, decrease of 50% or greater from maximum response in the level of granulocytes/ platelets or reduction in the hemoglobin concentration by at least 2 g/dl or transfusion dependence in the absence of another explanation such as acute infection or hemorrhage. Disease progression was defined by: (1) 50% or more increase in the blast count compared to baseline or (2) 50% or greater decrement from maximum response in level of the granulocytes or platelets, or (3) reduction in hemoglobin concentration by 2 g/ dl or transfusion dependence not due to other comorbid conditions. Patients were removed from the study for relapse of disease, progression of disease or severe adverse reactions.
Assessment of lysine-acetylated histones. Mononuclear cells were isolated from the patient's blood and bone marrow by means of density centrifugation and cytospins prepared. The slides were fixed in 95% ethanol-5% acetic acid for 1 min, and then the specimens were permeabilized and blocked for 40 min in phosphate-buffered saline that contained 10% goat serum, 1% bovine serum albumin and 0.3% Triton X-100. The slides were then incubated with anti-acetylated histone H4 antibody (Upstate Biotechnology Inc., Lake Placid, NY, USA) for 1 h. A Texas-red-conjugated immunoglobin G was used as a secondary antibody to reveal primary antibody localization. Staining with 4 0 ,6-diamidino-2-phenylinode was used to identify the nuclei.
Western blot analysis. Nuclei from blood and bone marrow mononuclear cells were isolated by lysis in a buffer containing 10 mM Tris-HCl (pH 6.5), 50 mM sodium bisulfite, 1% Triton X-100, 10 mM MgCl 2 and 8.6% sucrose, using a Dounce homogenizer. Histones were isolated by means of acid extraction as described previously. 28 Isolated histones (10-15 mg) were then separated in 17.5% polyacrylamide-0.1% sodium dodecyl sulfate minigels (Bio-Rad Laboratories, Hercules, CA, USA) and transferred to nitrocellulose filters (Schleicher & Schuell Inc., Keene, NH, USA). Hyperacetylated histones were detected by use of antibodies that specifically recognize the hyperacetylated forms of H3 and H4 (Upstate Biotechnology); histone-antibody complexes were visualized by chemiluminescence (Pierce Chemical Co., Rockford, IL, USA). As a control for the amount of protein loading, additional samples were run in parallel and stained with Ponceau Red.
Statistics
Ten evaluable patients were treated in this pilot study, which was designed to explore the feasibility of combination transcriptional modulating therapy (TMT). An evaluable patient was defined as a patient who had completed the 7 days of 5-azacytidine plus 5 days of sodium PB and undergone research testing at the prescribed points. Patients who were determined to be inevaluable for any reason were replaced. Safety data were described by organ system and assessed using standard NCI toxicity criteria. Histone acetylation studies were analyzed as described above and are reported qualitatively. Only descriptive statistics applied given the small number of patients under consideration.
Results
A total of 12 patients were accrued to the study. Ten patients had relapsed AML, whereas two had a MDS. Two patients were unable to complete therapy. One patient with multiply relapsed APL developed a peripheral vein thrombosis on day 5 of the 5-azacytidine therapy, hence the therapy was discontinued. The thrombosis was not thought to be related to the study drug, but instead to the coagulopathy associated with the patient's underlying disease. A second patient with relapsed AML had his white blood cell (WBC) count controlled on hydroxyurea, which was discontinued before starting the 5-azacytidine. Unfortunately, the patient developed a rapidly rising WBC count while receiving the 5-azacytidine therapy. The study drug was therefore discontinued on day 4 and the patient treated with a cytarabine-containing regimen to control the hyperleukocytosis.
The pretreatment characteristics of the 10 evaluable patients are shown in Table 1 . Included in the AML group were one patient with relapsed APL and one patient with t(8;21) AML. Of the patients with MDS, one was diagnosed with CMML-2 because of the presence of Auer rods, whereas the other patient had RAEB. Four of the eight AML patients had previously received cytarabine-based chemotherapy. The APL patient was heavily pretreated with cytarabine, idarubicin, ATRA and arsenic trioxide. The MDS patients had received no chemotherapy before.
Clinical response
Overall, we observed a 50% response rate (PR þ SD) in patients treated with this combination regimen. While none of the patients achieved a CR, three patients did achieve a PR and two other patients had SD; four of these five patients received multiple cycles of combination TMT. In fact, these were the only four patients who received more than one cycle of therapy (overall median number of cycles -2.5, range 1-4). Two of these patients achieved a PR, whereas two had SD. Only one patient developed a significant hematologic response with normalization of the peripheral blood counts. This patient had CMML-2 and met all the criteria for CR in the blood and bone marrow, except for the presence of Auer rods in a myeloid precursor detected on scanning the post-treatment aspirate. This finding led the patient's response to be downgraded to a PR. This patient presented with a WBC of 37 400/ml composed of 40% monocytes, which decreased to 8900/ml following the first cycle of the 5-azacytidine/PB. The WBC normalized following the second cycle (7900/ml with 7% monocytes). She received a total of two courses of therapy and achieved her maximal response following course no. 2. The patient then went on to allogeneic bone marrow transplantation from an HLA-identical related donor, 48 days after the second cycle of TMT. She is currently alive without disease approximately 39 months post-transplant. A second patient with MDS maintained SD through three cycles of treatment, but developed worsening transfusion requirements following the fourth cycle and, at that point, was determined to have progressive disease.
The other three responses occurred in patients with AML. One patient had relapsed following an allogeneic BMT from a matched unrelated donor. Her blasts disappeared from both the peripheral blood (from 50 to 0%) and bone marrow biopsy after one cycle of therapy. She then had a second BMT from an HLA match-unrelated donor, but later relapsed and died approximately 7 months post-transplant. The second patient was a 77-year-old male who had developed AML following a 2-year history of MDS. He received 5-azacytidine/PB as his initial form of treatment. The blast count in the bone marrow decreased from 80% at diagnosis to a low of 12% at the time of the third cycle. Despite the improvement in bone marrow blasts, the patient had no improvement in peripheral blood counts and expired owing to intracerebral hemorrhage in the setting of thrombocytopenia. The third patient had SD following the first cycle of therapy, but progressed following the next treatment. Sodium phenylbutyrate and 5-azacytidine in patients with AML or MDS P Maslak et al
All other AML patients failed to achieve a response, including one patient with relapsed APL and one patient with relapsed AML t (8;21) . Each progressed following the first cycle of therapy and were, therefore, taken off study and offered other therapy. The time to initial response was relatively rapid with a median of 31 days (range 21-43 days). The duration of response was rather short with a median of 45 days (range 37-136 days). As discussed above, two patients who achieved a PR proceeded to allogeneic stem cell transplantation at 37 and 63 days, respectively. The other partial responder died as a result of trauma, 45 days following documentation of maximal response. The patients with SD continued on therapy until progression of disease (usually three cycles of therapy).
Toxicity
The combination of 5-azacytidine and sodium PB was generally well tolerated. Seven patients completed all therapy in the outpatient setting, whereas three patients were hospitalized for neutropenic fever. Common non-hematologic toxicities are summarized in Table 2 . Nausea, dizziness, disorientation/ somnolence and fatigue were common side effects occurring in 80% of patients. These symptoms were associated with PB administration and they resolved within a few hours following completion of the infusion. Most of the patients developed an erythematous skin reaction at the site of the 5-azacytidine injection. Electrolyte abnormalities occurred in hospitalized patients treated with antibiotics and antifungals; these abnormalities responded to appropriate interventions.
As discussed above, there was one death during therapy in a patient with refractory thrombocytopenia who experienced a cerebral hemorrhage following head trauma. There were three episodes of neutropenic fever following therapy, which resulted in hospitalization and treatment with antimicrobials. One patient developed dyspnea on exertion secondary to atrial fibrillation approximately 2 weeks following the completion of the third cycle of therapy. The arrhythmia responded to medical cardioversion and the patient had no further dyspneic episodes or arrhythmia. The atrial fibrillation was not thought to be secondary to the study medications because of the prolonged time interval following treatment and the occurrence of symptoms.
Induction of histone hyperacetylation
Although Dnmts have been found in HDAC-containing complexes, we saw no change in the acetylated forms of histones H3 and H4 following therapy with 5-azacytidine. However, levels of acetylated histone H4 did increase, as expected, in the peripheral blood and/or bone marrow mononuclear cells following the PB portion of the therapy, in all 10 patients who completed at least one cycle of combination therapy. Changes in the acetylation status of histone H3 were more variable in the patient samples, as only three of 10 patients showed an increase in acetylated H3. Furthermore, the change in histone H4 acetylation was consistently greater than the change in histone H3 acetylation in the patient samples. A representative response is shown in Figure 1 .
Discussion
This pilot study evaluated the safety and activity of 5-azacytidine when combined with sodium PB in patients with myeloid malignancies. Overall, the combination therapy was well tolerated with most of the patients experiencing grade 1-2 nausea or local skin reactions to the 5-azacytidine injection, consistent with the reported clinical experience. The reported neurocorticol effects/depression seen with prolonged infusions of PB were observed, but at the dose of PB employed in this study, these sedating effects were reversible, resolving completely within a few hours after the cessation of drug. Additive toxicity was not seen in this trial and those patients who did not complete multiple cycles of the combination therapy were unable to do so owing to progression of their underlying disease. Most of the patients were treated with this regimen in the outpatient setting and no severe, non-reversible drug-related complications were seen in this group. The myelosuppressive properties of this regimen were difficult to assess, as the baseline peripheral blood counts were markedly compromised and many of the patients were already transfusion dependent. A decrease in blast count, however, did not translate into recovery of the peripheral blood counts in the patients with AML, although normalization of peripheral blood counts was observed in one MDS patient after two cycles of therapy. Similar to the pattern of response seen with single-agent 5-azacytidine, multiple cycles of TMT may be required to achieve its full biologic and clinical effect and the maximum number of cycles administered to the Sodium phenylbutyrate and 5-azacytidine in patients with AML or MDS P Maslak et al AML patients was only three. Given the aggressiveness of their disease, two of the patients treated on study proceeded to stem cell transplant as soon as it was clear that they were responding to this combination therapy.
We were able to demonstrate in vivo inhibition of histone deacetylation in the correlative laboratory studies. Histone H3 acetylation was more variably seen than was histone H4 acetylation both in the clinical samples and in the control. This finding may reflect the interplay between histone H3 acetylation and methylation. [29] [30] [31] Unless H3-K9 methylation is reversed, it may not be possible to reacetylate H3-K9 using HDAC inhibitors alone. In addition, no correlation was found between the Hyacetylation assays and clinical response. This may be explained by the limited duration of action of these hypomethylating agents and HDAC inhibitors. It also likely reflects the complex pathogenesis of these diseases.
Transcriptional repression, as a mechanism of action for the translocation-associated chimeric proteins, has specifically been modeled in AML for the PML/RARa and AML1/ETO fusion products. Two AML patients with these translocations (t(15;17) and t(8:21)) were included in this pilot study and both completed the prescribed therapy. However, neither patient was able to achieve a clinical response despite the biologic effect observed. Such findings once again underscore the complexity of targeting malignant transformation and reversing the malignant phenotype in a patient with a relapsed or refractory hematologic malignancy. The ability to modulate the acetylation and methylation status of the histones in the nucleosomes surrounding the DNA of key genes may establish an environment permissive for differentiation or apoptosis, but may not be sufficient in itself to accomplish these cellular events, without other proactive signals acting as a 'trigger' for such physiologic processes to occur.
Conclusion
In conclusion, our data demonstrate that combination therapy with an HDAC inhibitor and hypomethylating agent is feasible and has limited clinical activity in AML and MDS. Although safe and somewhat efficacious, this form of TMT may not be able to act rapidly enough for certain very aggressive malignancies. The in vivo effects on histone protein acetylation appear to be similar to those previously obtained in vitro; however, there was no correlation with clinical response. Targeting epigenetic modulation of gene expression represents a new strategy in the therapy of cancer. Future studies will build on this preliminary data investigating other histone deacetylating/ hypomethylating drug combinations and trying to extend the underlying hypothesis by adding potential 'triggers' for differentiation, with such agents as ATRA or G-CSF. 32, 33 
